[Paper/Press release] A new paper on NTTP-contaminated sitagliptin use and possible cancer risk has been published.

The present study aimed to determine if the use of NTTP-contaminated sitagliptin, in comparison with other dipeptidyl peptidase-4 (DPP-4) inhibitors, is associated with an increased cancer risk using the National Database (NDB), a comprehensive national claims database in Japan. As a result, Sitagliptin users (149,120 patients, 388,356 person-years) experienced 9,643 cancer incidences (2,483.0/100,000 person-years) versus 12,621 incidences (2,504.4/100,000 person-years) among other DPP-4 inhibitor users (199,860 patients, 503,952 person-years). No significant differences were found in any of the multivariable regression analysis, stratified analyses by cancer type, or sensitivity analyses. We observed no evidence to suggest an increased cancer risk among patients prescribed NTTP-contaminated sitagliptin, although continued investigation is needed.

To access the paper, click here : https://onlinelibrary.wiley.com/doi/10.1111/jdi.14281